02.23.24 -- No Playbook For Leqembi: Eisai's Long Game In Alzheimer's Disease

You might be aware that Sail Biomedicines was formed in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde. What you likely haven’t heard is the inside story of how the merger was executed. On the Business of Biotech, CEO Dr. Guillaume Pfefer takes us under the hood of Sail Biomedicines and its mission to marry evolution and AI to develop programmable medicines based on eRNA.

Explore findings from research into talent pool resilience in the biopharmaceutical industry that incorporate survey insights as well as external data to ensure a more accurate overview.

Combined with the inherent difficulty of the chemistry behind gene therapy development, its pace, structure, and funding dynamics are unique among treatment modalities.

Consider this proactive approach to patient recruitment that has the potential to ensure a more dynamic and responsive strategy and is suited for the rapidly changing landscape of clinical trials.

Early-stage development is an iterative process, continuously generating new data and insights to optimize the product based on emerging knowledge.

Explore how a stepwise approach for process characterization can help target the right experimental design and be tailored for different programs based on prior knowledge and experience.